Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease

Both nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have been associated with incident cardiovascular disease (CVD), independent of confounders. Causality has recently been inferred by Mendelian randomization studies. Although these findings have contributed to current guidelines that recommend screening for and treatment of cardiovascular risk factors, it not yet clear how to position NAFLD/MAFLD in cardiovascular risk estimation scores and, consequently, which treatment targets should be used. This review aims to provide practical tools as well as suggestions for further research in order to effectively prevent CVD events in patients with NAFLD/MAFLD.

Source: Endocrinology and Metabolism Clinics of North America - March 8, 2023 Category: Endocrinology Authors: Zhewen Ren, Anke Wesselius, Coen D.A. Stehouwer, Martijn C.G.J. Brouwers Source Type: research